Table 2.
Immunostaining for CCL2 and CCR2 in the skin and lymph nodes.
| Staining cell proportion in skin tissue, % | AOSD (n = 35) | HCs (n = 5) | Eczema (n = 5) | Lupus (n = 5) | Drug eruption (n = 5) |
|---|---|---|---|---|---|
| CCL2 | 5.3 ± 7.8 | 0.6 ± 0.5 | 3.4 ± 1.5 | 2.0 ± 1.0 | 7.0 ± 12.9 |
| p-value (vs. AOSD) | – | 0.03 | 0.43 | 0.78 | 0.84 |
| CCR2 | 24.7 ± 21.2 | 26.2 ± 23.5 | 5.2 ± 3.2 | 22.2 ± 29.1 | 6.2 ± 3.6 |
| p-value (vs. AOSD) | – | 0.84 | 0.01 | 0.32 | 0.01 |
| Staining cell proportion in lymph nodes, % | AOSD (n = 9) | Tuberculosis lymphadenitis (n = 5) | T cell lymphoma (n = 5) | Kikuchi’s disease (n = 5) | Reactive lymphadenopathy (n = 5) |
|---|---|---|---|---|---|
| CCL2 | 4.6 ± 6.0 | 16.0 ± 12.9 | 5.2 ± 3.6 | 9.6 ± 11.9 | 3.0 ± 2.9 |
| p-value (vs. AOSD) | 0.01 | 0.31 | 0.44 | 0.68 | |
| CCR2 | 26.8 ± 24.9 | 4.2 ± 3.6 | 6.4 ± 7.9 | 7.8 ± 7.6 | 4.8 ± 3.3 |
| p-value (vs. AOSD) | – | 0.02 | 0.06 | 0.1 | 0.04 |
AOSD adult-onset Still's disease, HCs healthy controls, CCR C–C motif chemokine receptor, CCL C–C motif ligand.